Classification of Alzheimer’s Disease Based on Deep Learning of Brain Structural and Metabolic Data

Huiquan Wang¹, Tianzi Feng², Zhe Zhao², Xue Bai³, Guang Han¹, Jinhai Wang¹, Zongrui Dai⁴, Rong Wang⁵, Weibiao Zhao⁴, Fuxin Ren⁵* and Fei Gao⁵*

¹ School of Life Sciences, Tiangong University, Tianjin, China, ² School of Electrical and Information Engineering, Tiangong University, Tianjin, China, ³ Department of Radiology, Qilu Hospital of Shandong University, Jinan, China, ⁴ Westa College, Southwest University, Chongqing, China, ⁵ Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

To improve the diagnosis and classification of Alzheimer’s disease (AD), a modeling method is proposed based on the combining magnetic resonance images (MRI) brain structural data with metabolite levels of the frontal and parietal regions. First, multi-atlas brain segmentation technology based on T1-weighted images and edited magnetic resonance spectroscopy (MRS) were used to extract data of 279 brain regions and levels of 12 metabolites from regions of interest (ROIs) in the frontal and parietal regions. The $t$-test combined with false discovery rate (FDR) correction was used to reduce the dimensionality in the data, and MRI structural data of 54 brain regions and levels of 4 metabolites that obviously correlated with AD were screened out. Lastly, the stacked auto-encoder neural network (SAE) was used to classify AD and healthy controls (HCs), which judged the effect of classification method by fivefold cross validation. The results indicated that the mean accuracy of the five experimental model increased from 96 to 100%, the AUC value increased from 0.97 to 1, specificity increased from 90 to 100%, and F1 value increased from 0.97 to 1. Comparing the effect of each metabolite on model performance revealed that the gamma-aminobutyric acid (GABA) levels in the parietal region resulted in the most significant improvement in model performance, with the accuracy rate increasing from 96 to 98%, the AUC value increased from 0.97 to 0.99 and the specificity increasing from 90 to 95%. Moreover, the GABA levels in the parietal region was significantly correlated with Mini Mental State Examination (MMSE) scores of patients with AD ($r = 0.627$), and the F statistics were largest ($F = 25.538$), which supports the hypothesis that dysfunctional GABAergic system play an important role in the pathogenesis of AD. Overall, our findings support that a comprehensive method that combines MRI structural and metabolic data of brain regions can improve model classification efficiency of AD.

Keywords: Alzheimer’s disease, deep learning, magnetic resonance imaging, magnetic resonance spectroscopy, feature extraction
INTRODUCTION

Alzheimer's disease (AD) is a progressive neurodegenerative disease that mainly manifests as cognitive decline and abnormal behavior (Zeng et al., 2021). The onset of AD is hidden, and thus it is difficult to identify in the early stages. However, as AD progresses, it seriously affects daily life and causes irreversible damage to the brain, resulting in a heavy burden on the patient's family and the healthcare system. At present, there is no effective clinical method to prevent or treat AD, and existing drugs are only able to slow down disease progression. As a result, early diagnosis of AD has become one of the biggest challenges currently facing medicine and society (Reitz and Mayeux, 2014; Vls et al., 2020). Magnetic resonance imaging (MRI), as the main method of neuroimaging, has been widely used to study the structure, function, and perfusion of the human brain. Notably, structural MRI is widely used in the early diagnosis of AD (Konrad et al., 2009). Previous studies have shown that cortical thickness and volume of hippocampus play a pivotal role in the classification between AD and healthy controls (Li et al., 2011).

However, functional changes in AD occur earlier than structural changes, i.e., AD patients show abnormal brain function in the early stage before impairment of brain structure has occurred (Bosco et al., 2017; Kamagata et al., 2020). For instance, a resting-state functional MRI study suggested that the activity in the default mode network may prove a sensitive and specific biomarker for early stage AD (Md et al., 2004; Wang et al., 2012).

Therefore, adopting structural MRI alone for the diagnosis of early AD has major limitations and its specificity and sensitivity are low. Importantly, previous studies have shown that AD also involves dysfunction of a variety of neurotransmitter systems, including the cholinergic system, glutamatergic (Glu) system, and gamma-aminobutyric acid (GABA) system (Zhang et al., 2015). Magnetic resonance spectroscopy (Munteanu et al., 2015; Vignoli et al., 2020) (MRS), which is a non-invasive technology that uses the principle of chemical shift to measure metabolite levels in the brain, has been widely used in studies of various neurological and mental diseases. For example, N-acetylaspartate (NAA) can reflect damage and loss of neuronal cells in brain tissue. Kantarci et al. (2007) and Carelli et al. (2015) found that NAA levels in the hippocampus can be used as an imaging marker to assess the progression of mild cognitive impairment to AD. GABA is an important inhibitory neurotransmitter (Jo et al., 2014) that regulates excitatory activity, thereby preventing overexcitement of neurons and oscillation activity of neural networks. Studies of AD animal models have indicated that abnormal function of the GABAergic system may be a common target of multiple abnormal signal pathways in AD (Danlei et al., 2020). Furthermore, abnormal function of the GABAergic system can lead to neuronal excitation-inhibition imbalance, which promotes the pathological spread of Aβ and tau and further aggravates cognitive impairment in AD patients. Additionally, studies of post-mortem brains have reported decreased GABA levels in the frontal and parietal brain tissues of AD patients (Kreisl et al., 2013; Salminen et al., 2016). The MEGA-PRESS (MEscher-GArwood-Point RESolved Spectroscopy) sequence has been applied to detect brain GABA levels in many neurologic and psychiatric disorders (Atagün et al., 2017; Murley et al., 2020; He et al., 2021).

However, only a few studies to date have combined structural data and metabolite levels of brain regions to establish an early diagnosis model of AD. (Thus, this study adopted multi-atlas segmentation technology based on high-resolution brain structure to automatically segment the brain to extract the structural data and then applied MEGA-PRESS sequence to detect the levels of metabolites.

With advances in artificial intelligence, deep learning has demonstrated a good classification effect for the diagnosis of AD (Ortiz et al., 2016; Suk et al., 2017; Liu et al., 2020). The convolutional neural network (CNN) (Abdulazeem et al., 2021) is often used as a modeling and classification tool to diagnose AD; however, CNN needs updating of several parameters within its network. With the increasing of hidden layers, CNN network will become complex, adding a lot of computing process. Stacked auto-encoder (SAE) (Suk et al., 2015; Ijjina and Mohan, 2016) is a deep learning network model for unsupervised learning that is widely used in various feature extraction and classification problems. SAE neural network has the function of feature selection, which can find the features of interest more easily (Cao et al., 2016). Combining with dense layer, SAE can used to perform supervised learning by achieving the approximation of complex function. The SAE neural network used in this study encodes the input data to obtain data characteristics and then decodes the transmitted data to realize the reconstruction of the input data. Its structure is relatively simple, the reconstruction speed is fast, and there is no requirement for a large sample size. In the present study, the SAE neural network was used to perform AD classification based on different types of input data, namely MRI structural data of brain regions and MRS metabolite levels of frontal and parietal regions. Moreover, the accuracy, the area under the curve (AUC) value, sensitivity, and specificity of the AD classification models were calculated in order to evaluate the impact of the addition of MRS metabolic data on the accuracy of the AD classification results.

MATERIALS AND METHODS

Study Design

This study was approved by the ethics committee of Shandong First Medical University and all participants or their legal guardians provided written informed consent. In total, 27 AD patients and 15 age-, sex-, and education-level matched healthy controls (HCs) were included in this study. AD patients were diagnosed according to the National Institute of Neurological and Communicative Disorders and the Alzheimer's Disease and Related Disorders Association criteria (NINCDS-ADRDA) (Dubois et al., 2007). The AD group comprised 11 men and 16 women with an average age of 65.95 ± 6.82 years and a mean Mini Mental State Examination Scale (MMSE) (Davatzikos et al., 2011) score of 18.78 ± 2.91. The HCs group comprised 8 males and 7 females with an average age of 63.87 ± 3.32 years and a mean MMSE score of 28.47 ± 0.96. The details are shown in...
The exclusion criteria for the AD group were as follows: (1) It may be dementia other than AD, such as vascular dementia, paralytic dementia, dementia syndrome caused by other brain or physical diseases, etc. (2) Those who are unable to cooperate with severely impaired speech expression, comprehension, severe visual and hearing impairment, and other reasons. The exclusion criteria for the AD and HCs group were as follows: (1) MRI contraindications. (2) A history of substance abuse.

### Data Acquisition

MRI data were acquired using the dual radio frequency transmission mode of a Philips 3.0T scanner (Achieva, TX) and 8-channel head coils as transmitting and receiving coils. The T1-weighted TFE sequence was used to obtain high-resolution 3D brain images. The scan related parameters were: pixel size = 1 × 1 × 1 mm³, matrix = 256 × 256, thickness = 1 mm, repetition time (TR) = 8.2 ms, echo time (TE) = 3.7 ms, reversal angle = 8°, and field of view (FOV) = 24 × 24 cm². On the 3D T1-TFE image, the regions of interest (ROIs) were located in the frontal and parietal regions with a size of 3 × 3 × 3 cm³. The frontal region was placed above the anterior half of the corpus callosum and parallel to the corpus callosum. The parietal region was placed in the middle region of the bilateral parietal region above the corpus callosum and parallel to the tangent line of the corpus callosum. The edges of all ROIs avoided touching the skull and bilateral lateral ventricles.

The MEGA-PRESS sequence was used for metabolite data collection. The scan parameters were as follows: scan time = 11 min, TR = 2,000 ms, TE = 68 ms, scan bandwidth = 1,000 Hz, and 320 averages. LCMODEL software was used to quantify the levels of metabolite in two ROIs. Since MEGA-PRESS technology obtains the GABA signal at 3.02 ppm, it also contains the signals of macromolecules and high carnosine, so the collected signal is GABA rather than pure GABA.

### T-test Analysis

In order to establish an accurate AD classification model, it is first necessary to screen out MRI structural data of brain regions and metabolite levels of ROIs that are closely related to AD. We used the independent samples t-test for multi-modal data analysis to achieve effective dimensionality reduction. The dataset comprising multi-modal data was used as the input data of the classification model, and the AD disease label was used as the target of the classification model. The multi-modal data included MRI structural data of brain regions and the levels of various metabolites in the frontal and parietal regions. The AD disease label is represented by 1 and 0, where 1 represents AD and 0 represents HCs. An FDR corrected p-value < 0.05 suggests that the multimodal data correlate with the target of the AD classification model, indicating that the difference is statistically significant (Hidalgo-Muñoz et al., 2014).

### Stacked Auto-Encoder Neural Network Modeling Method

#### Stacked Auto-Encoder Network Model

The SAE neural network is a deep neural network model for unsupervised feature recognition that is widely used in various feature extraction and classification problems. To achieve accurate classification of AD, this study uses a deep neural network composed of double hidden layer auto-encoders (AE). Among them, AE is a neural network with a three-layer structure comprising an input layer, hidden layer, and output layer. Each layer is fully connected. The target of SAE is to estimate the input data accurately while filtering the unnecessary information. By achieving this target, the encoder layers have lower dimensions than the original data, reducing the redundant information. Then, decoder layers are used to regenerate the feature map based on the encoder layers, gaining a novel dataset. The SAE neural network in this study is composed of one SAE model and one classification layers that includes two stages: unsupervised pre-training and supervised fine-tuning. The first stage pre-trains the AE of the SAE neural network in an unsupervised manner using a layer-by-layer greedy algorithm, i.e., an algorithm that uses the feature weights of the previous layer of the AE as the input data of the next layer in the order of front to back. Pre-training is performed layer by layer. In the second stage, add the label corresponding to the sample of this study and the weight value obtained in the previous stage, and use the MSE loss function to calculate the error between the predicted value and the real value. Then, according to the derivative of the loss function, the error is transmitted back along the minimum direction of the gradient to correct each weight value in the forward calculation formula. Finally, the whole training process of SAE neural network is completed. As shown in Figure 1, the overall structure of the AD classification model used in this study includes three main parts: (i) screening key data using the t-test and combining input datasets, (ii) using deep learning to train the classification model, and (iii) selecting the best model and classifying AD and HC.

**Table 1**

| Characteristics | AD group | HC group | P-value |
|-----------------|----------|----------|---------|
| Subject         | 27       | 15       | –       |
| Gender (M/F)    | 11/16    | 8/7      | 0.59    |
| Age             | 67.11 ± 7.18 | 63.87 ± 3.32 | 0.11    |
| MMSE            | 18.78 ± 2.91 | 28.47 ± 0.96 | <0.001  |

The data are presented as means ± standard deviations. AD, Alzheimer’s disease; HC, health controls.
select the best model. It is determined that the good SAE neural network has better sparsity, so as to avoid the dimension curse problem that may occur when the number of features is greater than the number of samples in the process of network training. In the pre-training stage, the learning rate of the model is set to 0.1, the batch size is set to 3, and the epochs are related to the number of training sets. In the formal training stage, the learning rate of the model is 1, the batch size is related to the number of training sets, the epochs are 15, and the activation function in the classification layer is the Sigmoid function.

Input Dataset Classification
In this study, in order to ensure the generalization ability of the constructed AD classification model and avoid over fitting,
of the model, the K-fold cross-validation method with K equal to 5 was selected to test the performance of the classification model. The 42 groups of sample datasets were divided into five parts, which take four of them as the training set to train the classification model each time and used the remaining one as the test set to judge the performance of the classification model. The experimental steps were repeated for five times. And the constructed AD classification model was evaluated by the overall results of the prediction set.

RESULTS

T-test Screening Results

Based on the t-test and FDR data correction results, a total of 58 multi-modal data features showing significant differences between groups were obtained (Table 2), including data for 54 MRI structural data of brain regions and 4 levels of metabolites.

To further verify whether these 58 multi-modal features are consistent with AD diagnosis, the correlation analysis was performed for each feature and the MMSE scores. Using the multi-modal data as the independent variable and the MMSE scores as the dependent variable, the r correlation coefficient was calculated to further verify the reliability of data selection. Figures 3A–D shows the regression results for the 4 metabolite levels and MMSE scores.

The range of the correlation r-values is (0.343, 0.694), indicating that the selected metabolite data have a strong correlation with MMSE and supporting that the selected 4 metabolites in the frontal and parietal regions correlated with AD symptoms.

Input Data Classification of Stacked Auto-Encoder Neural Network

As shown in Table 3, combining the multi-modal data according to the screening results resulted in 7 different AD classification models, respectively, labeled ①–⑦. The input dataset is multi-modal data composed of MRI structural data of brain regions and metabolites in different ROIs. The output dataset is the presence of AD (0 = HC, 1 = AD). Model ① includes the control group and the input dataset is the 54 MRI structural data of brain regions selected by the t-test. Model ② includes the 54 MRI structural data of brain regions combined with the 4 metabolites, including NAA/Cr in the frontal region and GABA+, Glu/Cr and NAA/Cr in the parietal region. Models ③–⑥ are the 4 input datasets obtained by combining the 54 structural of brain regions and the data for each metabolite selected by the t-test. Model ⑦ includes the 54 MRI structural data of brain regions combined with GABA+, Glu/Cr and NAA/Cr in the parietal region. The fivefold cross validation results of the seven models are shown in Supplementary Tables 1–7.

Comparison of the Alzheimer’s Disease Classification Accuracy of Different Models

In the study, the mean of the five experimental results in the fivefold cross-validation of each model was taken as the final experimental result. Figure 4 presents an intuitive comparison chart of the classification accuracy and AUC values of the 7 models.

As shown in Figure 4, comparing model ①, ②, and ⑦, adding the three metabolites of GABA+, Glu/Cr, and NAA/Cr in the parietal region increases the accuracy of AD classification from 96 to 100%, The AUC value from 0.97 to 1, indicating significant improvement in the classification performance.

Models ③–⑥ show the combinations of one of the 4 metabolites with the 54 MRI structural data of brain regions. Compared with model ① that includes only structural data, the AD classification accuracy of model ③, ④, and ⑤ with GABA+, Glu/Cr, and NAA/Cr in the parietal region, respectively, increased from 6 to 98%, and the AUC value was improved from 0.97 to 1.00. However, the AUC value of model ⑤ combined with NAA/Cr in the frontal region and brain structural data increased from 0.97 to 0.98, and the classification accuracy decreased from 97 to 82%.

From the results of linear regression between the metabolite data and MMSE in Table 4, the four metabolite data of GABA+, Glu/Cr, NAA/Cr in the parietal region and NAA/Cr in the frontal region had significant statistical significance with AD classification (p < 0.05). Moreover, the four regression models passed the F-test, and the GABA+ in the parietal region and MMSE regression models had the largest F statistics (F = 25.538). The results of the significance test further indicated...
TABLE 2 | Data screened using the t-test.

| Brain region                                      | P-value | Brain region                                      | P-value |
|---------------------------------------------------|---------|---------------------------------------------------|---------|
| Inferior frontal WM pars opercularis_R           | 0.0478  | Cingulum (cingulate gyrus)_L                      | 0.0199  |
| Inferior frontal WM pars orbitralis_R            | 0.0455  | Putamen_L                                         | 0.0199  |
| Superior frontal gyrus_L                         | 0.0418  | Middle Temporal WM_L                              | 0.0187  |
| posterior cingulate gyrus_R                      | 0.0400  | Superior corona radiata_L                         | 0.0187  |
| Angular gyrus_R                                  | 0.0387  | Nucleus accumbens_L                               | 0.0187  |
| Insula_L                                         | 0.0387  | Fusiform Gyrus_R                                  | 0.0163  |
| NAA/Cr_F                                         | 0.0379  | Fimbria_L                                         | 0.0162  |
| Parahippocampal gyrus_L                          | 0.0363  | Hippocampus_R                                     | 0.0162  |
| Superior temporal gyrus_R                        | 0.0356  | Lateral Fronto-Orbital WM_R                       | 0.0162  |
| Superior parietal gyrus_L                        | 0.0354  | Posterior Cingulate WM_L                          | 0.0162  |
| Splenium of corpus callosum_L                    | 0.0341  | Middle Temporal Gyrus_R                           | 0.0162  |
| Middle frontal gyrus (posterior segment)_L       | 0.0342  | Temporal Lobe Sulci_R                             | 0.0153  |
| Inferior fronto-occipital fasciculus_R           | 0.0342  | Inferior Frontal WM pars opercularis_L            | 0.0109  |
| Cingulum (hippocampus)_L                         | 0.0330  | Dorsal anterior cingulate gyrus_L                 | 0.0109  |
| Body of corpus callosum_L                        | 0.0305  | Middle Temporal Gyrus_L                           | 0.0103  |
| Substancia Nigra_R                               | 0.0305  | Inferior frontal gyrus pars opercularis_L         | 0.0103  |
| External capsule_R                               | 0.0294  | Nucleus accumbens_L                               | 0.0097  |
| Fusiform gyrus_L                                 | 0.0294  | Clustrum Complex_L                                | 0.0095  |
| Supramarginal gyrus_R                            | 0.0290  | BasalForebrain_R                                  | 0.0084  |
| Superior temporal gyrus_L                        | 0.0273  | Sylvian Fissure Temporal Lobe Part_L              | 0.0076  |
| Pole of middle temporal gyrus_L                  | 0.0253  | Amygdala_R                                        | 0.0076  |
| Anterior corona radiata_R                        | 0.0235  | Inferior Frontal WM pars Triangularis_L           | 0.0055  |
| BasalForebrain_R                                 | 0.0235  | Sylvian Fissure Frontal Lobe Part_L               | 0.0041  |
| Occipital Lobe Sulci_R                           | 0.0235  | Superior longitudinal fasciculus_L                | 0.0035  |
| Subcallosal anterior cingulate WM_L              | 0.0235  | Amygdala_L                                        | 0.0031  |
| Inferior temporal gyrus_L                        | 0.0231  | NAA/Cr_P                                          | 0.0020  |
| GABA + /Cr_P                                     | 0.0206  | Caudate_tail_L                                    | 0.0020  |
| Superior corona radiata_R                        | 0.0199  | Glu/Cr_P                                          | 0.0003  |
| Middle Frontal WM (posterior segment)_L          | 0.0199  | Hippocampus_L                                     | 0.0003  |

FDR corrected p < 0.05. L, left; R, right; F, frontal region; P, parietal region. WM, white matter.

that GABA + in the parietal region was the key data affecting AD classification.

DISCUSSION

The results of this study show that the addition of the three metabolites GABA +, Glu/Cr, and NAA/Cr in the parietal region significantly improved AD classification. And of the various metabolites tested, the GABA + levels of the parietal region contributed the most to the model classification results, suggesting that it is a key feature that affects AD classification.

Structural MRI data alone are widely used in the diagnosis of AD. For example, atrophy of the hippocampus and entorhinal region are characteristic structural changes of AD. Previous studies have shown that the sensitivity of an AD model containing only MRI structural features is 93% and the specificity is 86% (Westman et al., 2010). In this study, the AD classification accuracy of the model containing MRI structural data of brain regions is 96%, and the specificity is 90%. In addition to MRI structural data of brain regions, changes in metabolites have been shown to be effective biological markers of AD. In the study, the addition of all 4 metabolites increased the accuracy of AD classification from 96 to 100%, the AUC value from 0.97 to 1.00 and the specificity from 90 to 100%. Previous studies have used multivariate data analysis to explore the effect of adding metabolite data to AD diagnostic models, which found that adding metabolite characteristics to a structural diagnostic model increased sensitivity to 97% and specificity to 94% (Westman et al., 2010). Some researchers (Ahmed et al., 2020) have used deep learning to classify early AD patients and controls using MRS data. The addition of MRS data increased the model classification accuracy to 93.3% and the specificity to 89.47%, indicating great detection efficiency. The above findings are consistent with the results of the present study, indicating that an AD classification method that combines MRI structural data of brain regions with metabolite levels has higher specificity and classification accuracy than a structural model alone, which can effectively improve the accuracy of AD diagnosis.

This study also analyzed the effects of four metabolites on the classification of AD. Figure 3 shows that the correlation of GABA + in the parietal region is the highest and that of NAA/Cr in frontal region is the lowest. The results showed that GABA + levels in the parietal region were the key data affecting
FIGURE 3 | Regression analysis of 4 metabolites including the parietal region GABA +, Glu/Cr, NAA/Cr levels and the frontal region NAA/Cr levels with MMSE.
(A) MMSE scores were positively associated with the GABA + levels of the parietal region ($r = 0.624, p = 0.0165$). (B) MMSE scores were positively associated with the Glu/Cr levels of the parietal region ($r = 0.095, p = 0.0068$). (C) MMSE scores were negatively associated with the NAA/Cr levels of the frontal region ($r = -0.155, p = 0.0412$). (D) MMSE scores were positively associated with the NAA/Cr levels of the parietal region ($r = 0.360, p = 0.000002$).

AD classification. The model including GABA + had the highest accuracy and specificity, which increased the classification accuracy from 96 to 98%, AUC value from 0.97 to 0.99 and the specificity from 90 to 95%. The significant $p$-value of NAA/Cr of the frontal region was between 0.01 and 0.05, which was statistically significant. The significant $p$-values of GABA +, Glu/Cr, and NAA/Cr in the parietal region were all less than 0.01, which had extremely significant statistical significance with MMSE. Moreover, the four regression models passed the F-test, and the GABA + levels of the parietal region and MMSE regression models had the largest F statistics ($F = 25.538$), which further indicated GABA + levels of the parietal region is the key data affecting AD classification. GABA, which is the main inhibitory metabolite in the human brain, is closely related to cognitive function and participates in the regulation of various advanced cognitive behaviors such as learning and memory (Schmitz et al., 2017; Scholl et al., 2017). Studies of AD animal models have found that abnormal function of the GABAergic system may be a common target of multiple abnormal signal pathways in AD. Dysfunctional GABAergic system leads to neuronal excitation-inhibition imbalance, which will promote the pathological spread of Aβ and tau and further aggravate cognitive impairment in AD patients (Danlei et al., 2020). Moreover, excitatory-inhibitory imbalance is considered an important cause of cognitive impairment, and GABAergic system is an important regulatory factor for the excitation-inhibition balance (Duncan et al., 2014). Decreased parietal GABA levels may lead to regional excitation-inhibition imbalance, which may result in neuronal overexcitation. Thus, selectively manipulating the synthesis or release of GABA to correct excitation-inhibition imbalance could be a potential treatment target for AD. Overall, our findings provide further evidence that parietal GABA level is a key feature affecting the classification of AD. Combined with MRI structural data and metabolite characteristics, the accuracy of AD classification will be significantly improved.

Although our findings support that the method proposed in this study has potential clinical applications in AD research, our study is still subject to some limitations. First, the sample

TABLE 3 | Input datasets of each classification model.

| Parameter combination |
|-----------------------|
| ① 54 Structural data |
| ② 54 Structural data + 4 Metabolite levels data |
| ③ 54 Structural data + GABA + in the parietal region |
| ④ 54 Structural data + Glu/Cr in the parietal region |
| ⑤ 54 Structural data + NAA/Cr in the frontal region |
| ⑥ 54 Structural data + NAA/Cr in the parietal region |
| ⑦ 54 Structural data + 3 Metabolic Data in the parietal region |

4 Metabolite Levels Data include GABA +, Glu/Cr and NAA/Cr in the parietal region and NAA/Cr in the frontal region.
FIGURE 4 | Comparison of the classification accuracy and AUC value of 7 different AD classification models. The input dataset of model $\textcircled{1}$ are 54 structural data. The input dataset of model $\textcircled{2}$ are 54 structural data and 4 metabolite levels data including GABA $+\text{, Glu/Cr, NAA/Cr}$ in the parietal region and NAA/Cr in the frontal region. The input dataset of model $\textcircled{3}$ are 54 structural data and GABA $+$ in the parietal region. The input dataset of model $\textcircled{4}$ are 54 structural data and Glu/Cr in the parietal region. The input dataset of model $\textcircled{5}$ are 54 structural data and NAA/Cr in the frontal region. The input dataset of model $\textcircled{6}$ are 54 structural data and NAA/Cr in the parietal region. The input dataset of model $\textcircled{7}$ are 54 structural data and GABA $+$, Glu/Cr and NAA/Cr in the parietal region.

comprised only 42 AD patients and controls, and small number of samples may slow the convergence speed of neural network, causing overfitting and low generalization capability. Second, our study lacked information about longitudinal changes of structural and metabolic data in patients with AD. Thus, future studies should expand the number of participants and explore the impact of longitudinal data on the classification of AD over time, and we will try to apply novel method in prediction. Such as applying RNN or LSTM to classify. Lastly, we did not collect brain function and perfusion data in this study, such as resting-state functional MRI and arterial spin labeling perfusion. We plan to add the above data to subsequent studies to establish an AD diagnostic model involving three dimensions, namely structure, function, and metabolism.

TABLE 4 | Four metabolite data in the parietal and frontal regions of ROI and MMSE linear regression analysis.

| p  | Person’s r | R square | Adjusted R square | F statistic |
|----|-------------|----------|------------------|------------|
| GABA $+\text{.P}$ | 0.000010 | 0.624 | 0.390 | 0.374 | 25.538 |
| Glu/Cr $\text{.P}$ | 0.000137 | 0.555 | 0.306 | 0.291 | 17.798 |
| NAA/Cr $\text{.F}$ | 0.026000 | 0.343 | 0.118 | 0.095 | 5.329 |
| NAA/Cr $\text{.P}$ | 0.000035 | 0.593 | 0.351 | 0.335 | 21.680 |

p, p-value of significance; F, in the frontal region; P, in the parietal region.

CONCLUSION

In summary, compared to AD classification models that only involves MRI brain region structural data, the addition of the metabolite levels in the parietal regions significantly improved AD classification performances. Moreover, the GABA $+$ levels of the parietal region were the key feature affecting AD classification, which supports the hypothesis that dysfunctional GABAergic system plays an important role in the pathogenesis of AD. Our findings support that a comprehensive method that combines MRI structural and metabolic data of brain regions can improve model classification efficiency of AD.

DATA AVAILABILITY STATEMENT

The datasets presented in this article are not readily available because the corresponding data may expose privacy. Requests to access the datasets should be directed to corresponding authors.

ETHICS STATEMENT

This study was approved by the ethics committee of Shandong First Medical University and all participants or their legal guardians provided written informed consent. Written informed
consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

FG, HW, ZZ, GH, and JW contributed to the conception and design of this study. FG and FR summarize the database. ZD and XB were statistically analyzed. HW and FG wrote the first draft of the manuscript. TF, RW, and WZ wrote various parts of the manuscript. All authors participated in the revision, reading, and approval of the submitted version of the manuscript.

FUNDING

This work was supported by the National Natural Science Foundation of China for Young Scholars (grant no. 81601479), the Taishan Scholars Program (grant no. tsqn201812147), the Fundamental Research Funds by Tianjin Municipal Education Commission (grant no. 2019KJ022), the Natural Science Foundation of Tianjin (grant no. 20JCQNJC00150) and the Medical Health Science and Technology Project of Tianjin Health Commission (grant no. QN20015), the Shandong Provincial Natural Science Foundation of China (grant nos. ZR2021MH030, ZR2021MH355), Jinan Science and Technology Development Program of China (No. 202019098), and the Academic Promotion Programme of Shandong First Medical University (grant no. 2019QL023).

REFERENCES

Abdulazeem, Y., Bahgat, W. M., and Badawy, M. (2021). A CNN based framework for classification of Alzheimer's disease. *Neural. Comput. Appl.* 33, 10415–10428. doi: 10.1007/s00521-021-05799-w

Ahmed, O. B., Fezani, S., Menuel, C. G., Fezei, L., and Fernandez-Maloigne, C. (2020). *DeepMRS: An End-to-End Deep Neural Network for Dementia Disease Detection using MRS Data*. Iowa City, IA: IEEE Computer Society. doi: 10.1109/ISBI45749.2020.9098419

Atag˘n, M. ˙I, ˙ Sıkoˇglu, E. M., Soykan, Ç, Serdar S¸leyman, C., Ulusoy-Kaymak, S., Ça˘kyoilü, A., et al. (2017). Persisyevan GABA levels in schizophrenia and bipolar disorder. *Neurosci. Lett.* 637, 70–74. doi: 10.1016/j.neulet.2016.11.051

Bosco, P., Redolfi, A., Bocchetta, M., Ferrari, C., Mega, A., Galluzzi, S., et al. (2017). The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: a European Alzheimer's disease consortium study. *Alzheimers Dement.* 13, 1013–1023. doi: 10.1016/j.jalz.2017.01.019

Cao, L. L., Huang, W. B., and Sun, F. C. (2016). Building feature space of extreme learning machine with sparse denoising stacked-autoencoder. *Neurocomputing* 174, 60–71. doi: 10.1016/j.neucom.2015.02.096

Carelli, V., Musumeci, O., Caporali, L., Zanna, C., Del Dotto, V., La Morgia, C., et al. (2015). Syndromic parkinsonism and dementia associated with OPA1 missense mutations. *Ann. Neurol.* 78, 21–38. doi: 10.1002/ana.24410

Danle, B., Wen, L., Wu, Z., and Shen, Y. (2020). GABAergic dysfunction in excitatory and inhibitory (E/I) imbalance drives the pathogenesis of Alzheimer's disease. *Alzheimers Dement.* 16, 1312–1329. doi: 10.1002/alz.2012088

Davatzikos, C., Bhatt, P., Shaw, L. M., Batmanghelich, K. N., and Trojanowski, J. Q. (2011). Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. *Neurobiol. Aging* 32, e19–e2322. doi: 10.1016/j.neurobiolaging.2010.05.023

Dubois, B., Feldman, H. H., Jacova, C., Dekosky, S. T., Barberger-Gateau, P., Cummings, J., et al. (2007). Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. *Lancet Neurol.* 6, 734–746. doi: 10.1016/S1474-4422(07)70178-3

Duncan, N. W., Wibking, C., and Northoff, G. (2014). Associations of regional GABA and glutamate with intrinsic and extrinsic neural activity in humans—A review of multimodal imaging studies. *Neurosci. Biobehav. Rev.* 47, 36–52. doi: 10.1016/j.neubiorev.2014.07.016

He, J. L., Mikkelsen, M., Huddleston, D. A., Crocetti, D., Cecil, K. M., Singer, H. S., et al. (2021). Frequency and intensity of premonitory urges-to-tic in tourette syndrome is associated with supplementary motor area GABA+ levels. *Mov. Disord.* 37, 563–573. doi: 10.1002/mds.28868

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnagi.2022.927217/full#supplementary-material

Hidalgo-Muñoz, A. R., Javier, R., Gorriz, J. M., and Pablo, P. (2014). Regions of interest computed by SVM wrapped method for Alzheimer's disease examination from segmented MRI. *Front. Aging Neurosci.* 6:20. doi: 10.3389/fnagi.2014.00020

Ijima, E. P., and Mohan, C. K. (2016). Classification of human actions using pose-based features and stacked auto encoder. *Pattern Recognit. Lett.* 83, 268–277. doi: 10.1016/j.patrec.2016.03.021

Jo, S., Yarishkin, O., Hwang, Y. J., Chun, Y. E., Park, M., Woo, D. H., et al. (2014). GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease. *Nat. Med.* 20, 886–896. doi: 10.1038/nm.3639

Kamagata, K., Andica, C., Hatano, T., Ogawa, T., Takeshige-Amano, H., Ogaki, K., et al. (2020). Advanced diffusion magnetic resonance imaging in patients with Alzheimer's and Parkinson's diseases. *Neural Regen. Res.* 15, 1590–1600. doi: 10.4103/1673-5374.276326

Kantarci, K., Weigand, S. D., Petersen, R. C., Boeve, B. F., Knopman, D. S., Gunter, J., et al. (2007). Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. *Neurobiol. Aging* Exp. Clin. Res. 28, 1330–1339. doi: 10.1016/j.neurobiolaging.2006.06.018

Konrad, C., Ubas, T., Nebel, C., Arolt, V., Toga, A. W., and Narr, K. L. (2009). Defining the human hippocampus in cerebral magnetic resonance images: an overview of current segmentation protocols. *Neuroimage* 47, 1185–1195. doi: 10.1016/j.neuroimage.2009.05.019

Kreid, W. C., Hyoung, L. C., Meghan, M. G., Joseph, S., Jenko, K. J., Nobuyo, K., et al. (2013). In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. *Brain* 136, 2228–2238. doi: 10.1093/brain/awt145

Liu, M., Li, F., Yan, H., Wang, K., and Xu, M. (2020). A multi-model deep convolutional neural network for automatic hippocampus segmentation and classification in Alzheimer's disease. *Neuroimage* 208:116459. doi: 10.1016/j.neuroimage.2019.116459

Liu, Y., Pajanien, T., Zhang, Y., Westman, E., Wahlund, L. O., Simmons, A., et al. (2011). Combination analysis of neuropsychological tests and structural MRI measures in differentiating AD, MCI and control groups—the AddNeuroMed cohort study. *Neurobiol. Aging* 32, 1198–1206. doi: 10.1016/j.neurobiolaging.2010.05.023

Md, G., Srivastava, G., Al, R., and Menon, V. (2004). Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. *Proc. Natl. Acad. Sci. U.S.A* 101, 4637–4642

Munteanu, C. R., Fernandez-Lozano, C., Abad, V. M., Alvarez-Melis, M., Fernandez-Maloigne, C., Al, R., and Menon, V. (2004). Default-mode network activity during a working memory task: an fMRI study. *Brain* 127, 1693–1706. doi: 10.1093/brain/awh296

Munteanu, C. R., Fernandez-Lozano, C., Abad, V. M., Pita Fernandez, S., Alvarez-Melis, M., Fernandez-Maloigne, C., Al, R., and Menon, V. (2004). Default-mode network activity during a working memory task: an fMRI study. *Brain* 127, 1693–1706. doi: 10.1093/brain/awh296
Murley, A. G., Rouse, M. A., Simon, J. P., Ye, R., Hezemans, F. H., Claire, O., et al. (2020). GABA and glutamate deficits from frontotemporal lobar degeneration are associated with disinhibition. *Brain* 143, 3449–3462. doi: 10.1093/brain/awaa305

Ortiz, A., Munilla, J., Gorriz, J. M., and Ramírez, J. (2016). Ensembles of deep learning architectures for the early diagnosis of the alzheimer’s disease. *Int. J. Neural Syst.* 26:1650025.

Reitz, C., and Mayeux, R. (2014). Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. *Biochem. Pharmacol.* 88, 640–651. doi: 10.1016/j.bcp.2013.12.024

Salminen, A., Jouhten, P., SarajaRvi, T., Haapasalo, A., and Hiltunen, M. (2016). Hypoxia and GABA shunt activation in the pathogenesis of Alzheimer’s disease. *Neurochem. Int.* 92, 13–24. doi: 10.1016/j.neuint.2015.11.005

Schmitz, T. W., Correia, M. M., Ferreira, C. S., Prescott, A. P., and Anderson, M. (2017). Hippocampal GABA enables inhibitory control over unwanted thoughts. *Nat. Commun.* 8:1311. doi: 10.1038/s41467-017-00956-z

Scholl, J., Kolling, N., Nelsisen, N., Stagg, C. J., Harmer, C. J., and Rushworth, M. F. (2017). Excitation and inhibition in anterior cingulate predict use of past experiences. *Elife* 6:e20365. doi: 10.7554/eLife.20365

Suk, H. I., Lee, S. W., and Shen, D. (2015). Latent feature representation with stacked auto-encoder for AD/MCI diagnosis. *Brain Struct. Funct.* 220, 841–859. doi: 10.1007/s00429-013-0687-3

Suk, H. I., Lee, S. W., and Shen, D. (2017). Deep ensemble learning of sparse regression models for brain disease diagnosis. *Med. Image Anal.* 37, 101–113. doi: 10.1016/j.media.2017.01.008

Vignoli, A., Paciotti, S., Tenori, L., Eusebi, P., and Parnetti, L. (2020). Fingerprinting alzheimer’s disease by 1h nuclear magnetic resonance spectroscopy of cerebrospinal fluid. *J. Proteome Res.* 19, 1696–1705. doi: 10.1021/acs.jproteome.9b00850

Vs, A., Mg, A., Mp, A., Mc, B., Car, A., Ys, A., et al. (2020). Enlightening the advancements in electrochemical bioanalysis for the diagnosis of Alzheimer’s disease and other neurodegenerative disorders. *J. Pharm. Biomed. Anal.* 189:113437. doi: 10.1016/j.jpba.2020.113437

Wang, L., Roe, C. M., Snyder, A. Z., Brier, M. R., Thomas, J. B., Xiong, C., et al. (2012). Alzheimer disease family history impacts resting state functional connectivity. *Ann. Neurol.* 72, 571–577. doi: 10.1002/ana.23643

Westman, E., Wahlund, L. O., Foy, C., Poppe, M., Cooper, A., Murphy, D., et al. (2010). Combining MRI and MRS to distinguish between Alzheimer’s disease and healthy controls. *J. Alzheimer's Dis.* 22, 171–181. doi: 10.3233/JAD-2010-100168

Zeng, H. M., Han, H. B., Zhang, Q. F., and Bai, H. (2021). Application of modern neuroimaging technology in the diagnosis and study of Alzheimer’s disease. *Neural Regen. Res.* 16, 73–79. doi: 10.4103/1673-5374.286957

Zhang, B., Ferman, T. J., Boeve, B. F., Smith, G. E., and Kantarci, K. (2015). MRS in mild cognitive impairment: early differentiation of dementia with lewy bodies and Alzheimer’s disease. *J. Neuroimag.* 25, 269–274. doi: 10.1111/jon.12138

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wang, Feng, Zhao, Bai, Han, Wang, Dai, Wang, Zhao, Ren and Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.